What is a stock summary page? Click here for an overview.
Business Description
Redhill Biopharma Ltd
NAICS : 325412
ISIN : US7574681034
Share Class Description:
RDHL: ADRDescription
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.97 | |||||
| Equity-to-Asset | -0.26 | |||||
| Debt-to-Equity | -0.08 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -32.19 | |||||
| Beneish M-Score | 6.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -84.7 | |||||
| 3-Year EBITDA Growth Rate | 83.4 | |||||
| 3-Year EPS without NRI Growth Rate | 86.9 | |||||
| 3-Year FCF Growth Rate | 82.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.16 | |||||
| 9-Day RSI | 33.92 | |||||
| 14-Day RSI | 35.63 | |||||
| 3-1 Month Momentum % | -60.4 | |||||
| 6-1 Month Momentum % | -71.6 | |||||
| 12-1 Month Momentum % | -82.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.54 | |||||
| Quick Ratio | 0.37 | |||||
| Cash Ratio | 0.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -191.7 | |||||
| Shareholder Yield % | -161.66 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -116.6 | |||||
| 3-Year ROIIC % | -62.49 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
| PS Ratio | 0.25 | |||||
| EV-to-EBIT | 0.13 | |||||
| EV-to-EBITDA | 0.14 | |||||
| EV-to-Forward-EBITDA | -3.75 | |||||
| EV-to-Revenue | -0.13 | |||||
| EV-to-Forward-Revenue | 1.37 | |||||
| EV-to-FCF | 0.11 | |||||
| Price-to-GF-Value | 0.95 | |||||
| Earnings Yield (Greenblatt) % | 769.23 | |||||
| FCF Yield % | -286.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RDHL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Redhill Biopharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.043 | ||
| EPS (TTM) ($) | - | ||
| Beta | 5.72 | ||
| 3-Year Sharpe Ratio | -0.36 | ||
| 3-Year Sortino Ratio | -0.84 | ||
| Volatility % | 51.94 | ||
| 14-Day RSI | 35.63 | ||
| 14-Day ATR ($) | 0.204192 | ||
| 20-Day SMA ($) | 2.08119 | ||
| 12-1 Month Momentum % | -82.85 | ||
| 52-Week Range ($) | 1.71 - 20.275 | ||
| Shares Outstanding (Mil) | 1.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Redhill Biopharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Redhill Biopharma Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Redhill Biopharma Ltd Frequently Asked Questions
What is Redhill Biopharma Ltd(RDHL)'s stock price today?
The current price of RDHL is $1.85. The 52 week high of RDHL is $20.27 and 52 week low is $1.71.
When is next earnings date of Redhill Biopharma Ltd(RDHL)?
The next earnings date of Redhill Biopharma Ltd(RDHL) is 2025-08-29 Est..
Does Redhill Biopharma Ltd(RDHL) pay dividends? If so, how much?
Redhill Biopharma Ltd(RDHL) does not pay dividend.
Guru Commentaries on NAS:RDHL
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers